What it isOral broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.
Why this oneUsed for community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis, with strong activity against respiratory pathogens including S. pneumoniae.
What limits itCarries the fluoroquinolone class risks of tendon rupture, peripheral neuropathy, CNS effects and QT prolongation, and a maculopapular rash is notably common with courses beyond 7 days.
BOXED WARNING Fluoroquinolone class: disabling, potentially irreversible tendinitis/tendon rupture, peripheral neuropathy, and CNS effects - discontinue immediately if any occur; may exacerbate myasthenia gravis (avoid with known MG history); reserve for ABECB only when no alternative treatment options
FDA dosing
Population
Start
Target
Max
Acute bacterial exacerbation of chronic bronchitis (reserve for patients with no alternative options)
Adults
320 mg QD x 5 days
320 mg QD; do not exceed recommended dose/duration
Community-acquired pneumonia (mild-moderate) due to S. pneumoniae, H. influenzae, M. pneumoniae, or C. pneumoniae
Adults
320 mg QD x 5 days
320 mg QD; do not exceed recommended dose/duration
Community-acquired pneumonia (mild-moderate) due to known/suspected MDRSP, K. pneumoniae, or M. catarrhalis
Adults
320 mg QD x 7 days
320 mg QD; do not exceed recommended dose/duration
Renal CrCl >40 mL/min: no adjustment. CrCl <=40 mL/min (incl. hemodialysis or CAPD): 160 mg q24h
Hepatic No adjustment needed
Instructions
With or without food; swallow whole with a liberal amount of liquid
Choice of 5- vs 7-day CAP regimen guided by initial sputum culture
Available strengths
tab 320 mg
Contraindications
History of hypersensitivity to any fluoroquinolone antibiotic (class cross-reactivity)
Cautions
Tendinitis and tendon rupture (class; disabling, potentially irreversible) - discontinue immediately if symptoms
Peripheral neuropathy - discontinue immediately if symptoms
CNS effects - discontinue immediately if symptoms
Myasthenia gravis exacerbation - avoid with known history of MG
Rash (3.5% vs 1.1% comparator; led to discontinuation in 0.8%)
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Gemifloxacin is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.
⚠ BOXED WARNINGS
Tendinitis and tendon rupture
Peripheral neuropathy
CNS effects
Myasthenia gravis exacerbation
Principal riskBoxed warning: fluoroquinolone class risks of disabling tendinitis/tendon rupture, peripheral neuropathy, CNS effects, and exacerbation of myasthenia gravis.